JP7504367B2 - 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 - Google Patents

抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 Download PDF

Info

Publication number
JP7504367B2
JP7504367B2 JP2023522667A JP2023522667A JP7504367B2 JP 7504367 B2 JP7504367 B2 JP 7504367B2 JP 2023522667 A JP2023522667 A JP 2023522667A JP 2023522667 A JP2023522667 A JP 2023522667A JP 7504367 B2 JP7504367 B2 JP 7504367B2
Authority
JP
Japan
Prior art keywords
cancer
sod
pharmaceutical composition
tumor
superoxide dismutase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023522667A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022244757A5 (https=
JPWO2022244757A1 (https=
Inventor
志偉 喬
愛美 本田
匠太 秋元
友樹 佐々木
紀子 梶
耕一郎 福田
徹 水島
健一郎 田中
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSASHINO UNIVERSITY
LTT Bio Pharma Co Ltd
Original Assignee
MUSASHINO UNIVERSITY
LTT Bio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MUSASHINO UNIVERSITY, LTT Bio Pharma Co Ltd filed Critical MUSASHINO UNIVERSITY
Publication of JPWO2022244757A1 publication Critical patent/JPWO2022244757A1/ja
Publication of JPWO2022244757A5 publication Critical patent/JPWO2022244757A5/ja
Application granted granted Critical
Publication of JP7504367B2 publication Critical patent/JP7504367B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023522667A 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 Active JP7504367B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021083610 2021-05-18
JP2021083610 2021-05-18
PCT/JP2022/020473 WO2022244757A1 (ja) 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2022244757A1 JPWO2022244757A1 (https=) 2022-11-24
JPWO2022244757A5 JPWO2022244757A5 (https=) 2023-12-13
JP7504367B2 true JP7504367B2 (ja) 2024-06-24

Family

ID=84141593

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023522667A Active JP7504367B2 (ja) 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Country Status (11)

Country Link
US (1) US20240261375A1 (https=)
EP (1) EP4353251A4 (https=)
JP (1) JP7504367B2 (https=)
KR (1) KR102843447B1 (https=)
CN (1) CN117279657A (https=)
AU (1) AU2022278242B2 (https=)
CA (1) CA3220333A1 (https=)
CO (1) CO2023017275A2 (https=)
MX (1) MX2023013777A (https=)
TW (1) TWI867299B (https=)
WO (1) WO2022244757A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178511A1 (ru) * 2024-02-21 2025-08-28 Евгений Владимирович ГРИГОРЬЕВ Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040980A1 (ja) 2004-10-12 2006-04-20 Asahi Glass Company, Limited レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
JPH04135485A (ja) * 1990-09-28 1992-05-08 Seikagaku Kogyo Co Ltd 白金錯体及び抗腫瘍剤
JP3232542B2 (ja) 1993-01-08 2001-11-26 宇部興産株式会社 ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼ誘導体及びその製造法
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
US6221848B1 (en) * 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
JP2001002585A (ja) * 1999-06-22 2001-01-09 Ltt Kenkyusho:Kk レシチン化スーパーオキシドジスムターゼ含有抗線維化剤
JP3792487B2 (ja) 1999-06-24 2006-07-05 株式会社Ｌｔｔバイオファーマ レシチン化スーパーオキシドジスムターゼ含有医薬組成物
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
JP2002080395A (ja) * 2000-08-31 2002-03-19 Ltt Institute Co Ltd 心筋傷害処置剤
ES2375797T3 (es) 2003-01-21 2012-03-06 Genervon Biopharmaceuticals Llc Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización.
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2006169128A (ja) 2004-12-13 2006-06-29 Ltt Bio-Pharma Co Ltd 熱傷治療剤
JP4867540B2 (ja) 2006-09-20 2012-02-01 日本精工株式会社 無段変速装置
US20100143321A1 (en) * 2006-12-19 2010-06-10 Ltt Bio Pharma Co., Ltd. Therapeutic composition for interstitual pneumonia
JP5459827B2 (ja) 2009-03-13 2014-04-02 株式会社Ｌｔｔバイオファーマ 慢性閉塞性肺疾患改善剤
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
JP6545926B2 (ja) * 2012-11-30 2019-07-17 株式会社ナノエッグ 手足症候群治療用組成物
RU2017106172A (ru) 2014-07-31 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
EP2985036A3 (en) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
US11197862B2 (en) 2015-07-16 2021-12-14 Xomics Biopharma, Inc. Methods of preventing toxicity of platinum drugs
JP6650612B2 (ja) 2015-10-06 2020-02-19 パナソニックＩｐマネジメント株式会社 照明制御装置及び照明システム

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040980A1 (ja) 2004-10-12 2006-04-20 Asahi Glass Company, Limited レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DRUG AND CHEMICAL TOXICOLOGY，2018年，Vol. 41, No. 4，pp. 476-485
Inflammation and Regeneration，2006年，Vol. 26, No.2，pp. 113-120
Life Sciences，2015年，Vol. 130，pp. 81-87

Also Published As

Publication number Publication date
EP4353251A1 (en) 2024-04-17
CN117279657A (zh) 2023-12-22
US20240261375A1 (en) 2024-08-08
AU2022278242B2 (en) 2024-11-14
CO2023017275A2 (es) 2023-12-20
MX2023013777A (es) 2023-12-04
TW202313100A (zh) 2023-04-01
WO2022244757A1 (ja) 2022-11-24
KR20240008844A (ko) 2024-01-19
JPWO2022244757A1 (https=) 2022-11-24
BR112023024140A2 (pt) 2024-02-06
TWI867299B (zh) 2024-12-21
AU2022278242A1 (en) 2023-11-30
EP4353251A4 (en) 2025-05-14
KR102843447B1 (ko) 2025-08-06
CA3220333A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
Qiao et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan
US11723947B2 (en) Anti-senescence compounds and uses thereof
JP6030622B2 (ja) 癌の阻害剤としてのｍｕｃ−１細胞質ドメインペプチド
Sebastian et al. Microtubules and cell division: Potential pharmacological targets in cancer therapy
Shi et al. Oxidative stress-driven DR5 upregulation restores TRAIL/Apo2L sensitivity induced by iron oxide nanoparticles in colorectal cancer
US11622990B2 (en) VAP polypeptide and use thereof in preparation of drug for targeted diagnosis and treatment of tumor
EP3263107B1 (en) Block copolymer conjugate of physiologically active substance
JP7504367B2 (ja) 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物
Zhan et al. Semen Strychni Pulveratum and vomicine alleviate neuroinflammation in amyotrophic lateral sclerosis through cGAS-STING-TBK1 pathway
Xu et al. Biguanides decorated albumin nanoparticles loading nintedanib for synergic enhanced hepatocellular carcinoma therapy
US12448624B2 (en) Modified nucleic acid having improved treatment efficacy, and anticancer pharmaceutical composition containing same
CN114621325B (zh) 一种纤连蛋白靶向多肽及其在促进肿瘤失巢凋亡及化疗增敏中的应用
Li et al. A novel antibody-KSP inhibitor conjugate improves KSP inhibitor efficacy in vitro and in vivo
RU2845522C2 (ru) Фармацевтическая композиция для лечения или профилактики расстройства, связанного с введением противоракового средства
CA2807707A1 (en) Compositions and methods for treating cancer
CN114126660A (zh) 药物复合物及其制备方法和用途
HK40100859A (zh) 用於治疗或预防伴随抗癌剂给药的障碍的医药组合物
BR112023024140B1 (pt) Uso de uma superóxido dismutase lecitinizada para tratar ou prevenir um distúrbio associado com a administração de um agente anticâncer
HK1212920A1 (zh) 使用麦胶蛋白肽治疗癌症的套件和方法
KR20220001246A (ko) 췌장암 예방 또는 치료용 조성물
CN112294829A (zh) 红景天苷在制备治疗或预防癌症的药物中的应用
US20130259944A1 (en) Methods and compositions for treating cancer with platinum particles
Li et al. “Capture and kill” circulating fibrocytes by cisplatin prodrug loaded albumin disrupt the progress of pulmonary fibrosis in mice
CN120754077A (zh) 一种抗肿瘤组合物及其应用
SAMUEL et al. CISPLATIN-INDUCED NEPHROTOXICITY IN WISTAR RATS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20231124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240531

R150 Certificate of patent or registration of utility model

Ref document number: 7504367

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150